Beijing Luzhu Biotechnology Co., Ltd.
北京綠竹生物技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2480)

VOLUNTARY ANNOUNCEMENT SUCCESSFUL COMPLETION OF PHASE II CLINICAL TRIAL OF RECOMBINANT HERPES ZOSTER VACCINE CANDIDATE LZ901 IN THE PRC

This announcement is made by Beijing Luzhu Biotechnology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders of the Company and potential investors on the latest business updates of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the phase II clinical trial of LZ901 in the People's Republic of China (the "**PRC**") has been completed successfully in May 2023. The results are statistically and clinically meaningful, and demonstrated a favorable safety profile. The Company is in the course of advancing the multi-center, randomized, double-blinded and placebo-controlled phase III clinical trial of LZ901 in the PRC, and targets to commence the same as early as possible.

ABOUT THE PHASE II CLINICAL TRIAL IN THE PRC

The phase II clinical trial of LZ901 was designed as a randomized, double-blinded and placebo-controlled clinical trial. The primary objectives of this clinical trial are to evaluate the immunogenicity and safety of different doses of LZ901 in healthy people aged between 50 to 70 years old. The secondary objective of this clinical trial is to evaluate the immune persistence of different doses of LZ901 in healthy people aged between 50 to 70 years old. A total of 450 subjects aged between 50 to 70 years old were enrolled in the phase II clinical trial of LZ901.

Highlights of the phase II clinical trial results in the PRC are set out below:

– in terms of immunogenicity studies, the geometric mean concentration ("**GMC**"), geometric mean titer ("**GMT**") and the positive conversion rate of antibody in the high-dose LZ901 group were significantly higher than those in the low-dose cohorts. On the other hand, the GMC, GMT and the positive conversion rate of antibody in the high-dose and low-dose LZ901 group were significantly higher than those in the placebo group; and

– in terms of safety studies, adverse events ("**AEs**") in the trial mainly occurred within 0-7 days, and the incidence rate of Grade I, Grade II and Grade III AEs of the trial vaccines were approximately 23.74%, 6.02% and 1.00%, respectively. No Grade IV AEs and no serious AEs had been observed during the phase II clinical trial of LZ901 in the PRC.

The phase II clinical trial data provide definitive basis for the phase III clinical trial of LZ901. The dosage for the phase III clinical trial is determined to be 100 μg/0.5mL/vial, and the immunization program shall consist of two doses, with the second dose being administered 30 days after the first dose.

ABOUT LZ901

LZ901 is a recombinant herpes zoster vaccine candidate independently developed by the Group, and is the core product of the Group. It is developed based on the varicella-zoster virus ("**VZV**") glycoprotein E-fragment crystallizable region, and has a tetrameric molecular structure to prevent shingles caused by VZV for adults aged 50 years and older. LZ901 is designed on the basis of making full use of the mechanism of the human immune system for processing foreign antigens, and prevents the occurrence of herpes zoster and related complications caused by herpes zoster, including postherpetic neuralgia.

ABOUT THE COMPANY

The Company is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Since its inception in 2001, the Company has focused on human medicine and has established technology platforms with its understanding of immunology and protein engineering, which empowers the Company to develop its recombinant vaccine and antibody product candidates with favorable efficiency, high purity and improved stability.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that LZ901 will ultimately be successfully developed and marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Beijing Luzhu Biotechnology Co., Ltd.
Mr. KONG Jian
Chairman and Executive Director

Hong Kong, May 30, 2023

As at the date of this announcement, the Board comprises Mr. KONG Jian, Ms. JIANG Xianmin and Ms. ZHANG Yanping as executive Directors; Mr. MA Biao and Mr. KONG Shuangquan as non-executive Directors; and Mr. LEUNG Wai Yip, Mr. LIANG Yeshi and Ms. HOU Aijun as independent non-executive Directors.